These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 38299867)
1. Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT). Johnson MG; Strizki JM; Jensen E; Cohen J; Katlama C; Fishchuk R; Ponce-de-León A; Fourie N; Cheng C-Y; McCoy D; Vesnesky M; Norice CT; Zhang Y; Williams-Diaz A; Brown ML; Carmelitano P; Grobler JA; Paschke A; De Anda C Microbiol Spectr; 2024 Mar; 12(3):e0356323. PubMed ID: 38299867 [TBL] [Abstract][Full Text] [Related]
2. Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial. Johnson MG; Puenpatom A; Moncada PA; Burgess L; Duke ER; Ohmagari N; Wolf T; Bassetti M; Bhagani S; Ghosn J; Zhang Y; Wan H; Williams-Diaz A; Brown ML; Paschke A; De Anda C Ann Intern Med; 2022 Aug; 175(8):1126-1134. PubMed ID: 35667065 [TBL] [Abstract][Full Text] [Related]
3. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C; N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868 [TBL] [Abstract][Full Text] [Related]
4. Coinfections with Other Respiratory Pathogens among Patients with COVID-19. Sreenath K; Batra P; Vinayaraj EV; Bhatia R; SaiKiran K; Singh V; Singh S; Verma N; Singh UB; Mohan A; Bhatnagar S; Trikha A; Guleria R; Chaudhry R Microbiol Spectr; 2021 Sep; 9(1):e0016321. PubMed ID: 34287033 [TBL] [Abstract][Full Text] [Related]
5. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults. Caraco Y; Crofoot GE; Moncada PA; Galustyan AN; Musungaie DB; Payne B; Kovalchuk E; Gonzalez A; Brown ML; Williams-Diaz A; Gao W; Strizki JM; Grobler J; Du J; Assaid CA; Paschke A; Butterton JR; Johnson MG; De Anda C NEJM Evid; 2022 Feb; 1(2):EVIDoa2100043. PubMed ID: 38319179 [TBL] [Abstract][Full Text] [Related]
6. Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. Johnson MG; Strizki JM; Brown ML; Wan H; Shamsuddin HH; Ramgopal M; Florescu DF; Delobel P; Khaertynova I; Flores JF; Fouche LF; Chang SC; Williams-Diaz A; Du J; Grobler JA; Paschke A; De Anda C Infection; 2023 Oct; 51(5):1273-1284. PubMed ID: 36648627 [TBL] [Abstract][Full Text] [Related]
7. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423 [TBL] [Abstract][Full Text] [Related]
8. Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial. Strizki JM; Grobler JA; Murgolo N; Fridman A; Johnson MG; Du J; Carmelitano P; Brown ML; Paschke A; De Anda C Infect Dis Ther; 2023 Dec; 12(12):2725-2743. PubMed ID: 37995070 [TBL] [Abstract][Full Text] [Related]
9. Respiratory Pathogen Coinfections in SARS-CoV-2-Positive Patients in Southeastern Wisconsin: A Retrospective Analysis. Scott SJ; Pfotenhauer B; Weiner JJ; Hilleshiem J; Khubbar M; Bhattacharyya S Microbiol Spectr; 2021 Oct; 9(2):e0083121. PubMed ID: 34668725 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the Respiratory Viral Panel PCR Test Results Before and After COVID-19 Pandemic]. Alp A; Taşçı O; Ergin A; Köseoğlu Eser Ö Mikrobiyol Bul; 2022 Oct; 56(4):667-681. PubMed ID: 36458713 [TBL] [Abstract][Full Text] [Related]
12. Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro. Liu D; Leung KY; Lam HY; Zhang R; Fan Y; Xie X; Chan KH; Hung IF Virus Res; 2024 Jul; 345():199371. PubMed ID: 38621598 [TBL] [Abstract][Full Text] [Related]
13. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. Arribas JR; Bhagani S; Lobo SM; Khaertynova I; Mateu L; Fishchuk R; Park WY; Hussein K; Kim SW; Ghosn J; Brown ML; Zhang Y; Gao W; Assaid C; Grobler JA; Strizki J; Vesnesky M; Paschke A; Butterton JR; De Anda C NEJM Evid; 2022 Feb; 1(2):EVIDoa2100044. PubMed ID: 38319178 [TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
15. Rhinovirus as the main co-circulating virus during the COVID-19 pandemic in children. Varela FH; Sartor ITS; Polese-Bonatto M; Azevedo TR; Kern LB; Fazolo T; de David CN; Zavaglia GO; Fernandes IR; Krauser JRM; Stein RT; Scotta MC J Pediatr (Rio J); 2022; 98(6):579-586. PubMed ID: 35490727 [TBL] [Abstract][Full Text] [Related]
16. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review. Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098 [TBL] [Abstract][Full Text] [Related]
17. The circulation of Non-SARS-CoV-2 respiratory viruses and coinfections with SARS-CoV-2 during the surge of the Omicron variant. Eldesouki RE; Uhteg K; Mostafa HH J Clin Virol; 2022 Aug; 153():105215. PubMed ID: 35717769 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance and role of coinfections with respiratory pathogens among individuals with confirmed severe acute respiratory syndrome coronavirus-2 infection. Trifonova I; Christova I; Madzharova I; Angelova S; Voleva S; Yordanova R; Tcherveniakova T; Krumova S; Korsun N Front Public Health; 2022; 10():959319. PubMed ID: 36117597 [TBL] [Abstract][Full Text] [Related]
19. Coinfection of SARS-CoV-2 and Other Respiratory Pathogens. Ma L; Wang W; Le Grange JM; Wang X; Du S; Li C; Wei J; Zhang JN Infect Drug Resist; 2020; 13():3045-3053. PubMed ID: 32922049 [TBL] [Abstract][Full Text] [Related]
20. Incidence and Outcome of Coinfections with SARS-CoV-2 and Rhinovirus. Le Glass E; Hoang VT; Boschi C; Ninove L; Zandotti C; Boutin A; Bremond V; Dubourg G; Ranque S; Lagier JC; Million M; Fournier PE; Drancourt M; Gautret P; Colson P Viruses; 2021 Dec; 13(12):. PubMed ID: 34960797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]